Latest News and Press Releases

The new U.S. patent is expected to be valid until 2034, once granted RedHill and its co-development partner, IntelGenx Corp., recently announced the national approval of RIZAPORT™ in Germany...

TEL-AVIV, Israel, Feb. 18, 2016 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (NASDAQ:RDHL) (TASE:RDHL) (“RedHill” or the “Company”), an Israeli biopharmaceutical company primarily focused on the...

Dr. Almenoff previously served as President, Principal Executive Officer and Chief Medical Officer of Furiex Pharmaceuticals (now Actavis plc)Ms. Stevens previously served as Chief Corporate...

RedHill recently concluded a successful first-in-man pharmacokinetic (PK) study with BEKINDA™ 12 mg (RHB-102) proprietary formulation, to support the planned Phase II study for the treatment of...

Once granted, the new U.S. patent covering methods of use for RHB-104 is expected to be valid through 2029RHB-104 is undergoing a first Phase III study for the treatment of Crohn’s disease in...

TEL-AVIV, Israel, Feb. 09, 2016 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (NASDAQ:RDHL) (TASE:RDHL) (“RedHill” or the “Company”), an Israeli biopharmaceutical company primarily focused on the...

TEL-AVIV, Israel, Feb. 08, 2016 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (NASDAQ:RDHL) (TASE:RDHL) (“RedHill” or the “Company”), an Israeli biopharmaceutical company primarily focused on the...

TEL-AVIV, Israel, Feb. 02, 2016 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (NASDAQ:RDHL) (TASE:RDHL) (“RedHill” or the “Company”), an Israeli biopharmaceutical company primarily focused on the...

TEL-AVIV, Israel, Jan. 05, 2016 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (NASDAQ:RDHL) (TASE:RDHL) (“RedHill” or the “Company”), an Israeli biopharmaceutical company primarily focused on the...

TEL-AVIV, Israel, Dec. 30, 2015 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (NASDAQ:RDHL) (TASE:RDHL) (“RedHill” or the “Company”), an Israeli biopharmaceutical company primarily focused on the...